ARTICLE | Finance
Lava’s $83M series C exemplifies evolution of Novo Ventures’ investing
Danish firm has dramatically increased pace, size of investments
September 18, 2020 12:34 AM UTC
Over the past few years Novo Ventures has been ramping up the pace and size of its biotech investments, with Thursday’s $83 million series C round by γδ T cell engager company Lava the latest example of how the firm has evolved in the last five years.
The firm is now deploying what would be a good-sized VC fund annually, Novo Ventures’ Nanna Lüneborg told BioCentury...